TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15897211
Drug: Cognitive-oriented educational
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-oriented educational programme on assessment, treatment and management of somatisation (The Extended Reattribution and Management Model)
Study: 10080213
Drug: 0.005% latanoprost
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.005% latanoprost eyedrops once daily
Study: 10080213
Drug: 0.5% timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% timolol eyedrops twice daily
Study: 7956634
Drug: Pen-type insulin
Normalized name: insulin isophane Pen Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pen-type insulin syringes
Study: 30033695
Drug: Simple Triage
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple Triage and Rapid Treatment (START) system
Study: 22616411
Drug: Web-based animated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based animated pedagogical agents
Study: 18401285
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (IT‐Dex + HDPT)
Study: 8653235
Drug: Topical gel
Normalized name: Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical gel preparation of adrenaline (1:2000) and cocaine (4.7%)
Study: 2061364
Drug: Methylphenidate at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate at 0.15 mg/kg
Study: 2061364
Drug: Methylphenidate at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate at 0.50 mg/kg
Study: 6669629
Drug: Zopiclone (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zopiclone (7.5 mg) for 14 nights
Study: 6669629
Drug: Nitrazepam (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrazepam (5 mg) for 14 nights
Study: 30369062
Drug: Bevacizumab administered
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab administered on-demand every 4 weeks
Study: 30369062
Drug: Bevacizumab administered
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab administered on-demand every 8 weeks
Study: 23200183
Drug: Acetaminophen 1000
Normalized name: acetaminophen 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 1000 mg or 650 mg
Study: 17615999
Drug: Capsaicin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsaicin (150 mg)
Study: 7799495
Drug: Mastectomy or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mastectomy or breast-conserving surgery with radiation therapy
Study: 2136324
Drug: Amiodarone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (10 g cumulative dose)
Study: 7391988
Drug: Clonidine (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.15 mg over 10 min)
Study: 26496327
Drug: Genotype-guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotype-guided therapy (GGT) with peginterferon-alpha/ribavirin (HCV genotype 1: 48 weeks; HCV genotype 2/3: 24 weeks)
Study: 26496327
Drug: Response-guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Response-guided therapy (RGT) with peginterferon-alpha/ribavirin (HCV genotype 1: 48 or 24 weeks if baseline VL <400,000 IU/mL and RVR; HCV genotype 2/3: 24 or 16 weeks if RVR)
Study: 7856296
Drug: High-titre Edmonston-Zagreb
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-titre Edmonston-Zagreb (EZ-H), potency 5.7 log10/dose
Study: 7856296
Drug: Medium-titre Edmonston-Zagreb
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-titre Edmonston-Zagreb (EZ-M), potency 4.7 log10/dose
Study: 7856296
Drug: AIK-C, potency
Approvals — FDA: no, EMA: no, PMDA: no
Description: AIK-C, potency 5.5 log10/dose
Study: 2543223
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg conjugated equine estrogens for 21 days plus placebo during the last 10 days of each cycle
Study: 2543223
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg medrogestone per day for 10 days in conjunction with conjugated equine estrogens
Study: 8614420
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy followed by chemotherapy
Study: 29255347
Drug: Rosuvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (20 mg) administered once daily for 7 days as monotherapy
Study: 29255347
Drug: Ezetimibe (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe (10 mg) administered once daily for 7 days as monotherapy
Study: 23525316
Drug: 1 ml
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml of oral 25% glucose solution
Study: 23525316
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no oral glucose solution)
Study: 11719734
Drug: Low-sodium diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-sodium diet with rofecoxib (25 mg twice daily)
Study: 11719734
Drug: Intravenous furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous furosemide (20 mg)
Study: 8986145
Drug: Intermediate-dose methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intermediate-dose methotrexate (IDM) plus intrathecal methotrexate (IT MTX)
Study: 8318400
Drug: Dexamethasone administration
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone administration added to the antiemetic effect of ondansetron
Study: 8318400
Drug: Ondansetron as
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron as a single antiemetic agent
Study: 3539349
Drug: Cimetidine 1,600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 1,600 mg
Study: 25720077
Drug: Follicle Stimulating
Normalized name: follicle stimulating hormone
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Follicle Stimulating Hormone (FSH)
Study: 22110219
Drug: Luteinizing Hormone
Normalized name: LUTEINIZING HORMONE
DrugBank: Luteinizing hormone (DB14741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luteinizing Hormone (LH)
Study: 17852146
Drug: Ethnicity effect
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethnicity effect on hormone levels
Study: 17852146
Drug: Body Mass
Normalized name: Total Body Massager Item
Approvals — FDA: no, EMA: no, PMDA: no
Description: Body Mass Index (BMI) effect on hormone levels
Study: 17852146
Drug: Age effect
Normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Age effect on hormone levels
Study: 16110136
Drug: GM‐CSF 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM‐CSF 4 microg/kg/d subcutaneous
Study: 9952063
Drug: Morphine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine alone (15 mg)
Study: 21631446
Drug: Clomiphene treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomiphene treatment
Study: 21631446
Drug: Combination metformin/clomiphene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination metformin/clomiphene treatment
Study: 3230278
Drug: Methylprednisolone at
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone at a dosage of 0.25 mg/kg daily for 6 months
Study: 27312076
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plus ivabradine (I + SDT)
Study: 27312076
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (SDT)
Study: 24716466
Drug: Proactive tobacco
Normalized name: Tobacco leaf
DrugBank: Tobacco leaf (DB10710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proactive tobacco treatment intervention (proactive outreach with mailed invitations and telephone calls, access to free NRT and intensive telephone-based behavioral counseling)
Study: 22034522
Drug: Mind-body-based preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mind-body-based preventive intervention program (yoga postures, visualization, social exercises, breathing techniques); Duration: 5 weekly sessions.
Study: 20536952
Drug: Taspoglutide 20
Normalized name: Taspoglutide
DrugBank: Taspoglutide (DB14027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taspoglutide 20 mg once weekly for 4 weeks, followed by maintenance at 20 mg or titration to 30 mg or 40 mg for an additional 4 weeks.
Study: 20536952
Drug: Taspoglutide 30
Normalized name: Taspoglutide
DrugBank: Taspoglutide (DB14027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taspoglutide 30 mg once weekly for 4 weeks (after initial 20 mg).
Study: 20536952
Drug: Taspoglutide 40
Normalized name: Taspoglutide
DrugBank: Taspoglutide (DB14027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taspoglutide 40 mg once weekly for 4 weeks (after initial 20 mg).
Study: 8074020
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate infusion
Study: 7930251
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no nitrate infusion)
Study: 7930251
Drug: Nitrate administration
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate administration
Study: 25131978
Drug: Blood pressure-lowering
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood pressure-lowering treatment
Study: 26780184
Drug: Blood pressure-lowering
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood pressure-lowering treatment excluding baseline heart failure
Study: 26780184
Drug: Calcium antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium antagonists with concomitant use of diuretics, beta-blockers or renin-angiotensin system blockers
Study: 23732711
Drug: Daily use
Normalized name: ALCOHOL 75 mL in 100 mL TOPICAL GEL [Better For Daily Use EAAE Disinfectant]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily use of broad-spectrum sunscreen and 30 mg of β‐carotene
Study: 23732711
Drug: Daily use
Normalized name: ALCOHOL 75 mL in 100 mL TOPICAL GEL [Better For Daily Use EAAE Disinfectant]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily use of sunscreen and placebo
Study: 23732711
Drug: Discretionary use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discretionary use of sunscreen and 30 mg of β‐carotene
Study: 18537221
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba (120 mg daily)
Study: 10750855
Drug: Body lotion
Normalized name: LOBANA BODY LOTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Body lotion (specific product not named), applied 2 times a day for 14 days
Study: 10750855
Drug: Body lotion
Normalized name: LOBANA BODY LOTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Body lotion (specific product not named), applied to SLS-damaged skin
Study: 27923947
Drug: No mass
Approvals — FDA: no, EMA: no, PMDA: no
Description: No mass treatment (Control)
Study: 24439998
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of 300 mg bupivacaine
Study: 21904819
Drug: Nicotine inhalers
Normalized name: nicotine Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine inhalers (NI; 4 mg deliverable)
Study: 17440782
Drug: Intravenous ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketorolac (group A)
Study: 9347378
Drug: Moclobemide (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (mean dose 675 mg/day)
Study: 9347378
Drug: Imipramine (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (high dose 220 mg/day)
Study: 1609753
Drug: BCAA-enriched semielemental
Normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA-enriched semielemental formulation
Study: 1609753
Drug: Matched standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched standard semielemental formulation
Study: 29055449
Drug: APP-based home
Approvals — FDA: no, EMA: no, PMDA: no
Description: APP-based home therapy program for 3 months
Study: 29055449
Drug: Paper-based home
Normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paper-based home therapy program for 3 months
Study: 26369654
Drug: Hydrocodone ER
Normalized name: hydrocodone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone ER 15 mg with 4% alcohol
Study: 26369654
Drug: Hydrocodone ER
Normalized name: hydrocodone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone ER 15 mg with 20% alcohol
Study: 26369654
Drug: Hydrocodone ER
Normalized name: hydrocodone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone ER 15 mg with 40% alcohol
Study: 26369654
Drug: Hydrocodone ER
Normalized name: hydrocodone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone ER 15 mg with water
Study: 23983697
Drug: Postoperative intranasal
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative intranasal steroid
Study: 23983697
Drug: Postoperative intranasal
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative intranasal saline spray
Study: 21220471
Drug: PF299804 (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF299804 (45 mg/d) administered once daily continuously (schedule A) and intermittently (schedule B)
Study: 21220471
Drug: PF299804 (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF299804 (45 mg/d) administered once daily continuously (schedule A)
Study: 21220471
Drug: PF299804 (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF299804 (45 mg/d) administered intermittently (schedule B)
Study: 15213580
Drug: Methylphenidate combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate combined with multimodal psychosocial treatment (parent training, counseling, academic assistance, psychotherapy, social skills training)
Study: 15213580
Drug: Methylphenidate plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate plus attention control treatment (excluding specific aspects of psychosocial intervention)
Study: 10839593
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B oral suspension (ABOS), 100 mg/ml, 5 ml swish and swallow, four times daily for 14 days
Study: 10839593
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B oral suspension (ABOS) maintenance therapy, twice daily for up to 6 months
Study: 10839593
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B oral suspension (ABOS)
Study: 9387720
Drug: Piweiping capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piweiping capsule (PWPC)
Study: 1348797
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg ciprofloxacin per day
Study: 1348797
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg ciprofloxacin twice daily
Study: 27402726
Drug: Odanacatib 50
Normalized name: Odanacatib
DrugBank: Odanacatib (DB06670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Odanacatib 50 mg with low-fat meal
Study: 27402726
Drug: Odanacatib 50
Normalized name: Odanacatib
DrugBank: Odanacatib (DB06670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Odanacatib 50 mg with high-fat meal
Study: 24240353
Drug: Rewetting solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rewetting solution (control)
Study: 18421269
Drug: 900 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg/day calcium supplement
Study: 18421269
Drug: three servings
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: three servings of dairy products/day to achieve an additional 900 mg/day
Study: 18421269
Drug: placebo (<800
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (<800 mg/day calcium intake)
Study: 11111294
Drug: Slow infusion
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow infusion of Levovist at 1 ml/min (average dose 4.2 g)
Study: 11111294
Drug: Fast infusion
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast infusion of Levovist at 3 ml/min (average dose 7 g)
Study: 11111294
Drug: Bolus injections
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injections of Levovist (1 or 2 injections of 4 g each)
Study: 8856832
Drug: Low nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low nicotine training dose (10 micrograms/kg)
Study: 8856832
Drug: High nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High nicotine training dose (30 micrograms/kg)
Study: 30445386
Drug: Early-night wake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early-night wake therapy (EWT: sleep 3:00-7:00 am)
Study: 30445386
Drug: Late-night wake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late-night wake therapy (LWT: sleep 9:00 pm-01:00 am)
Study: 16996315
Drug: Amantadine 200
Normalized name: amantadine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine 200 mg/day started 1 day before surgery and continued for 14 days
Study: 16387120
Drug: Artificial liver
Normalized name: LIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificial liver support system (ALSS) treatment for 1 to 8 sessions
Study: 18680213
Drug: Conventional medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional medications
Study: 2230065
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg des-enkephalin-gamma-endorphin (DE gamma E) daily
Study: 98822
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate 2% nasal solution
Study: 28003352
Drug: No vaccine
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: No vaccine (arm C)
Study: 26448633
Drug: Bemiparin (3500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bemiparin (3500 IU subcutaneous for 7 days)
Study: 21784326
Drug: Homeopathic ear
Normalized name: Ring Relief Homeopathic Ear Drop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeopathic ear drops plus standard therapy
Study: 15112182
Drug: Intradermal (ID)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal (ID) vaccination with 5 microg of recombinant HBV vaccine every week for a total of 10 doses
Study: 15112182
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) vaccination with 20 microg at 0, 1, and 6 months
Study: 12959285
Drug: Lansoprazole (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (both doses)
Study: 3641693
Drug: Danazol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol (400 mg/d)
Study: 3641693
Drug: Gestrinone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gestrinone (5 mg/week)
Study: 24849084
Drug: Pasireotide (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide (900 μg subcutaneously twice daily for 7 days)
Study: 21246843
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with oral administration of Felodipine (group A)
Study: 21246843
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Felodipine only (group B)
Study: 18794650
Drug: Add-on of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Add-on of aripiprazole on a current regimen, wait for 4 weeks, and tapering of prior antipsychotics
Study: 18794650
Drug: Add-on of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Add-on of aripiprazole and simultaneous tapering of prior antipsychotics
Study: 10073816
Drug: Vascular surgery
Normalized name: acellular tissue engineered vessel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vascular surgery with perioperative intensive care treatment
Study: 2254672
Drug: Doxium 500
Normalized name: Dexium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxium 500 (1.5 g, 3 capsules/day)
Study: 7016973
Drug: Dicyclomine hydrochloride
Normalized name: Dicyclomine Hydrochloride
DrugBank: Dicyclomine (DB00804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dicyclomine hydrochloride 40 mg 4 times daily
Study: 22956531
Drug: Propofol administered
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol administered to reach and maintain a predetermined propofol effect-site concentration (Ce) based on the Marsh model
Study: 22956531
Drug: Propofol administered
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol administered to reach and maintain a predetermined propofol effect-site concentration (Ce) based on the Schnider model
Study: 18797455
Drug: CAP (capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAP (capecitabine single agent)
Study: 11819181
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) 500 mg po bid
Study: 10574107
Drug: Methylprednisolone 30
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone 30 mg/kg (100 ml) given by slow intravenous infusion 90-60 minutes before operation
Study: 1649422
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (40 patients)
Study: 1649422
Drug: Immunomodulating therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunomodulating therapy with Sintomodulin (20 patients)
Study: 25497747
Drug: Esmolol (500mcg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (500mcg/kg bolus followed by 100mcg/kg/min infusion)